ClinicalTrials.gg
Not yet recruitingNCT07713446Updated Jul 20, 2026

Effects of Task-Oriented Sit-to-Stand Training Using Immersive VR and PNF on Quality of Life in Chronic Stroke: Trial Protocol

An interventional study of Immersive Virtual Reality group and Proprioceptive Neuromuscular Facilitation group in Stroke and Cerebrovascular Accident (Stroke), sponsored by Universidad Nacional Autonoma de Mexico. Not yet recruiting at 1 site in Mexico. Open to participants aged 35 Years to 71 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Universidad Nacional Autonoma de Mexico · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
35 Years to 71 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the effects of two interventions based on different neurophysiological approaches on quality of life in individuals with chronic stroke. The interventions include Immersive Virtual Reality (IVR) and Proprioceptive Neuromuscular Facilitation (PNF), both focused on improving task-oriented sit-to-stand (STS) performance. A control group receiving conventional therapy will also be included. Participants in all three groups will receive 12 treatment sessions delivered three times per week over a 4-week period. The PNF group and the control group will receive 50-minute sessions. The IVR group will receive 10-20 minutes of IVR-based STS training combined with 30-40 minutes of conventional therapy, for a total session duration of 50 minutes.

The primary outcome will be quality of life, assessed using the Newcastle Stroke-Specific Quality of Life Measure (NEWSQOL). Secondary outcomes will include STS kinematic parameters (hip, knee, and ankle angular velocity, center of mass displacement, and STS duration), reaction time to gait iniciation (RTGI) measures, fall risk, lower-limb functional strength and endurance, and user satisfaction with the IVR intervention. The study will be conducted in two phases. The first phase will consist of a pilot study to assess the feasibility of the protocol and identify any necessary adjustments to the experimental procedures. The second phase will involve the implementation of the full randomized controlled trial to evaluate the effectiveness of the interventions.

This study aims to address the following research questions: (1) Does task-oriented STS training using IVR or PNF improve quality of life in individuals with chronic stroke to a greater extent than conventional therapy? (2) Do IVR- and PNF-based interventions lead to greater improvements in STS kinematics, reaction time and gait initiation, balance, and lower-limb functional strength and endurance compared with conventional therapy? (3) Is there an association between changes in STS kinematic parameters and improvements in stroke-specific quality of life following the intervention?

02

Conditions studied

  • Stroke
  • Cerebrovascular Accident (Stroke)

Browse trials for

Keywords

  • stroke
  • Propioceptive Neuromuscular Facilitation
  • PNF
  • Immersive Virtual Reality
  • Sit to Stand
03

In context

Stroke

8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.

This study's planned enrollment of 93 is above the median of 49 across 6,024 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Universidad Nacional Autonoma de Mexico is the lead sponsor of 28 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 71 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 35 to 71 years.
  • Diagnosis of ischemic or hemorrhagic stroke confirmed by medical records.
  • Chronic stroke, defined as ≥6 months and \<2 years since the stroke event.
  • Hemodynamically stable.
  • Ability to maintain sitting and standing positions independently or with minimal assistance.

Exclusion criteria

Exclusion Criteria:

  • Visual impairments that may interfere with the safe or effective use of immersive virtual reality.
  • Photosensitivity.
  • Cognitive impairment and/or communication deficits that prevent understanding or following study instructions.
  • Uncontrolled medical conditions or comorbidities that contraindicate participation in physical rehabilitation, including epilepsy, seizure disorders, cardiac arrhythmias, uncontrolled hypertension, or other significant cardiovascular conditions.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    Immersive Virtual Reality Group (IVR-G)

    Participants will receive task-oriented STS training using IVR combined with conventional physical therapy. IVR training will focus on weight shifting, center of mass displacement, postural control, motor coordination, and reaction time through gamified neurorehabilitation exercises. Treatment will be delivered three times per week for 4 weeks (12 sessions).

    Device: Immersive Virtual Reality group · Other: Conventional therapy group

  • Experimental
    Proprioceptive Neuromuscular Facilitation Group (PNF-G)

    Participants will receive task-oriented STS training based on PNF concept combined with conventional physical therapy. The intervention will focus on improving neuromuscular activation, postural control, weight-bearing symmetry, motor control, and functional STS performance. Treatment will be delivered three times per week for 4 weeks (12 sessions).

    Other: Proprioceptive Neuromuscular Facilitation group · Other: Conventional therapy group

  • Active comparator
    Convetional Therapy

    Participants will receive conventional physical therapy based on current stroke rehabilitation guidelines. Treatment will include functional mobility exercises, strengthening, balance training, weight-shifting activities, and functional task practice, including STS training as clinically indicated. Treatment will be delivered three times per week for 4 weeks (12 sessions).

    Other: Conventional therapy group

Interventions

  • DeviceImmersive Virtual Reality group

    Participants will receive task-oriented STS training using an immersive virtual reality system (Meta Quest 3 with NeuroRehab software). The intervention will include gamified neurorehabilitation exercises targeting weight shifting, center of mass displacement, postural control, motor coordination, anticipatory postural adjustments, and reaction time. The duration of IVR exposure will progressively increase up to 20 minutes per session to enhance tolerance and minimize cybersickness. Each session will also include conventional physical therapy, for a total treatment duration of 50 minutes. Participants will receive 12 sessions delivered three times per week over 4 weeks.

  • OtherProprioceptive Neuromuscular Facilitation group

    Participants will receive task-oriented STS training based on PNF concept. The intervention will include techniques aimed at improving neuromuscular activation, postural control, weight-bearing symmetry, motor learning, and functional performance during the different phases of the STS movement. The program will progress from biomechanical and neuromuscular preparation activities to functional STS practice and motor control training. Each session will also include conventional physical therapy, for a total treatment duration of 50 minutes. Participants will receive 12 sessions delivered three times per week over 4 weeks.

  • OtherConventional therapy group

    Participants will receive conventional physical therapy based on current stroke rehabilitation guidelines. Treatment will include active-assisted mobility exercises, strengthening, proprioceptive stimulation, management of spasticity when present, balance training in sitting and standing, weight-shifting activities, and functional task practice, including sit-to-stand training as clinically indicated. Each session will last 50 minutes. Participants will receive 12 sessions delivered three times per week over 4 weeks.

06

What researchers measure

Primary outcomes

  1. Quality of Life Measure

    Quality of life will be assessed using the Newcastle Stroke-Specific Quality of Life Measure (NEWSQOL), spanish version. The NEWSQOL is a validated 56-item questionnaire that evaluates the multidimensional impact of stroke across 11 domains: mobility, activities of daily living/self-care, pain/sensation, vision, cognition, communication, feelings, interpersonal relationships, emotions, sleep, and fatigue. Each item is scored on a 4-point scale ranging from 0 (no impact) to 3 (high impact). Domain scores are calculated by summing the corresponding item scores, with higher scores indicating a greater negative impact of stroke on quality of life. Changes in domain scores from baseline to post-intervention will be compared among groups.

    Time frame: Baseline (T0), immediately after completion of the 4-week intervention (T1), and 12 weeks after the end of the intervention (T2).

Secondary outcomes

  1. Sit-to-Stand duration

    Sit-to-Stand (STS) duration will be assessed using the PhysioMaster smartphone-based inertial measurement system. Raw inertial measurement unit (IMU) data will be exported to MATLAB for signal processing, including low-pass filtering at 5 Hz, before kinematic analysis. STS duration will be defined as the total time (seconds) required to complete the STS movement, from movement onset to achievement of a stable upright standing position. Three trials will be performed under standardized conditions, and the mean value will be used for statistical analysis. Shorter STS duration indicates more efficient functional performance during the STS task.

    Time frame: Baseline (T0), immediately after completion of the 4-week intervention (T1), and 12 weeks after the end of the intervention (T2)

  2. Balance and fall risk

    Balance and fall risk will be assessed using the Berg Balance Scale (BBS). The BBS evaluates performance during progressively challenging tasks, including transfers, standing, turning, reaching, and postural control activities. Each item is scored on a 5-point ordinal scale from 0 to 4, yielding a total score ranging from 0 to 56 points. Higher scores indicate better balance performance and lower fall risk. Changes in BBS scores from baseline to post-intervention and follow-up will be compared among groups.

    Time frame: Baseline (T0), immediately after completion of the 4-week intervention (T1), and 12 weeks after the end of the intervention (T2)

  3. Lower-limb functional strength and endurance

    Lower-limb functional strength and endurance will be assessed using the 30-Second Sit-to-Stand Test (30s-STS). Participants will be instructed to stand up and sit down from a standard chair as many times as possible within 30 seconds. The total number of completed repetitions will be recorded. Higher scores indicate greater lower-limb functional strength and endurance, whereas lower scores are associated with poorer functional performance and an increased risk of falls. Changes in the number of repetitions from baseline to post-intervention and follow-up will be compared among groups.

    Time frame: Baseline (T0), immediately after completion of the 4-week intervention (T1), and 12 weeks after the end of the intervention (T2)

  4. Sit to stand to gait transition time

    Sit to stand to gait (STS-GI) transition time will be assessed as the time required to initiate gait immediately after performing a STS task. Participants will be seated on a standardized chair with both feet placed comfortably on the floor and will be instructed to remain still until an auditory cue ("Go") is provided. Upon the cue, participants will stand up as quickly and safely as possible and immediately begin walking at their self-selected comfortable speed. The STS-GI will be the transition time (seconds), defined as the interval between the auditory cue and the onset of the first step, operationally defined as the instant when the leading foot leaves the ground (foot-off). Lower values indicate more efficient movement initiation and better functional mobility. Changes in time to start gate from baseline to post-intervention and follow-up will be compared among groups.

    Time frame: Baseline (T0), immediately after completion of the 4-week intervention (T1), and 12 weeks after the end of the intervention (T2).

  5. Peak trunk flexion angular velocity during STS

    Peak trunk angular velocity during the STS task will be measured using the PhysioMaster smartphone-based inertial measurement system. Raw IMU data will be exported to MATLAB and filtered at 5 Hz before analysis. The variable represents the maximum angular velocity (°/s) of trunk flexion achieved during the momentum-generation phase of the STS movement. Higher peak angular velocity reflects a faster trunk flexion strategy during the forward momentum generation required for successful STS performance.

    Time frame: Baseline (T0), immediately after completion of the 4-week intervention (T1), and 12 weeks after the end of the intervention (T2).

  6. Estimated anterior-posterior center of mass displacement during STS

    Estimated anterior-posterior CoM displacement during the STS task will be obtained using the PhysioMaster smartphone-based inertial measurement system. Raw IMU data will be exported to MATLAB for signal processing, including low-pass filtering at 5 Hz. The application estimates anterior-posterior CoM displacement (mm) from trunk inclination measured by the IMU using sensor-fusion algorithms and a simplified biomechanical model. Changes in estimated anterior-posterior CoM displacement will be interpreted together with STS duration and peak trunk angular velocity to characterize forward weight transfer and movement strategy during the STS task.

    Time frame: Baseline (T0), immediately after completion of the 4-week intervention (T1), and 12 weeks after the end of the intervention (T2).

Other outcomes

  1. User satisfaction with immersive virtual reality

    Participant satisfaction with the immersive virtual reality intervention will be assessed using the User Satisfaction Evaluation Questionnaire (USEQ). The USEQ is a 6-item instrument specifically designed to evaluate user satisfaction with virtual rehabilitation systems. Items assess enjoyment, perceived success, system control, clarity of information, comfort, and perceived rehabilitation benefit using a 5-point Likert scale ranging from 1 (not at all) to 5 (very much). Total scores range from 6 to 30 points, with higher scores indicating greater satisfaction with the virtual reality intervention. Scores ≥25 indicate high satisfaction, scores between 15 and 24 indicate moderate satisfaction, and scores \<15 indicate low satisfaction. This outcome will be assessed only in participants allocated to the IVR group.

    Time frame: After completion of the 4-week intervention (T1)

07

Study locations

1 site
  • Escuela Nacional de Estudios Superiores, Unidad León
    León, Guanajuato 37689, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Feb 2028, 13 months later.

Of 3,108 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 13 months is below that.

Counting every sponsor, half of 3,252 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2026
First posted
Jul 20, 2026
StartEst.
Jan 2027
Primary completionEst.
Feb 2028
CompletionEst.
Apr 2028
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07713446
Lead sponsor
Universidad Nacional Autonoma de Mexico
Collaborators
University of Cadiz
Responsible party
Carlos Rafael Palma Reyes (Adjunct Professor in the Bachelor of Physical Therapy Program, Escuela Nacional de Estudios Superiores, Universidad Nacional Autónoma de México (UNAM)., Universidad Nacional Autonoma de Mexico) — Principal investigator
First posted
Jul 20, 2026
Start date
Jan 2027 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Jul 20, 2026

Study contacts

Carlos R Palma Reyes, Master's Degree
Contact
cpalma@enes.unam.mx
+52 477 194 0800

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion